Fever-Tree Shares Fall Despite H1 Profit Beat on US Margin Drop

Fever-Tree shares fell over 5% despite reporting an H1 profit beat and retaining its full-year guidance, as investors focused on compressed U.S. margins caused by heavy marketing outlays. The pullback follows the British mixer maker's half-year financial update for the six months ending June 30.

"We have delivered a strong first half performance with growth across every one of our key regions," said Tim Warrillow, chief executive and co-founder of Fever-Tree, in a statement regarding the results.

Financial Performance and Regional Breakdown

For the period ending June 30, Fever-Tree reported adjusted revenue of £184.2 million and adjusted EBITDA of £20.1 million. These figures topped consensus expectations tracked by Jefferies, which had forecast revenue of £182.2 million and EBITDA of £19.5 million.

Performance varied across key geographic segments during the first half:

• United States: Revenue rose 11% year-on-year at constant currency to £66.9 million.
• UK and Europe: Continued to deliver steady underlying demand despite broader macroeconomic headwinds in the hospitality sector.
• Rest of World: Maintained positive volume trajectories across emerging urban distribution channels.

The Molson Coors Partnership and U.S. Margins

Despite the top-line growth in North America, segment profitability narrowed significantly. U.S. segment EBITDA fell to £4.1 million from £5.0 million a year earlier, driving the regional EBITDA margin down from 8.1% to 6.2%.

The margin compression stems directly from increased marketing investments tied to Fever-Tree's distribution arrangement with Molson Coors. Executives defended the expenditure as necessary to secure long-term market share in the competitive U.S. non-alcoholic and mixer category.

"Our partnership with Molson Coors is delivering, with sales momentum building, market share increasing," said Warrillow during the earnings call, according to an Investing.com earnings transcript.

Chief Financial Officer Andy Branchflower echoed that sentiment, noting that management anticipates a structural improvement in profitability as the venture matures. Branchflower stated that the company has "great confidence" in delivering a step change in margin due to profit guarantees tied to the partnership, alongside expectations of generating "at least £100 million of free cash flow across 2027 and 2028."

Capital Allocation and Cash Flow

Beyond operating performance, Fever-Tree updated investors on its balance sheet and shareholder return programs. In June, the board extended its ongoing share buyback program by an additional £30 million, bringing total announced buybacks for 2026 to £60 million.

That capital return initiative coincided with a reduction in corporate cash holdings. Total cash dropped to £68 million from £130 million a year earlier, reflecting outlays for buybacks, operational investments, and working capital requirements across its international supply chain.